Adrenomed
Berlin
About Adrenomed
Adrenomed is a privately-financed, clinical-stage biopharmaceutical company with a clear mission: to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. The Company’s lead product candidate is Adrecizumab, a clinical-stage, first-in-class monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity to treat life-threatening conditions associated with increased vascular leakage, congestion and shock. their unique treatment approach combines the therapeutic antibody with a specific diagnostic, which uses Adrenomedullin as the biomarker to identify patients. The most important target indications are sepsis and septic shock as well as acute heart failure. Adrenomed’s business is effectively secured by a strong IP position with granted patents in all major markets. Adrenomed is based in Hennigsdorf near Berlin, Germany.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $56.8M
- Funding stage: Late Stage Venture
- Last round: Convertible Note (Jul 2022)
- Website: adrenomed.com
- Phone: +49 (0) 3302 20 77 8 0
Industries & Categories
Biotechnology, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/adrenomed-14502 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.